Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing

American Journal of Clinical Pathology

Volumn 141, Issue 4, 2014, Pages 559-572

  Portier, Bryce P ^a   Kanagal Shamanna, Rashmi ^a   Luthra, Rajyalakshmi ^a   Singh, Rajesh ^a   Routbort, Mark J ^a   Handal, Brian ^a   Reddy, Neelima ^a   Barkoh, Bedia A ^a   Zuo, Zhuang ^a   Medeiros, L Jeffrey ^a   Aldape, Kenneth ^a   Patel, Keyur P ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AmpliSeq cancer panel; Ion torrent; Massarray; Mutant allele burden; Mutant allele frequency; Next generation sequencing; Sequenom

Indexed keywords

B RAF KINASE; ENDOTHELIAL CELL GROWTH FACTOR; ISOCITRATE DEHYDROGENASE 2; K RAS PROTEIN; N RAS PROTEIN; PROTEIN KINASE B; PROTEIN P53; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ALLELE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; GENE TARGETING; GENOTYPE; GNAQ GENE; HUMAN; HUMAN TISSUE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; MULTIPLEX POLYMERASE CHAIN REACTION; NEEDLE BIOPSY; PIK3CA GENE; POINT MUTATION; PRIMER EXTENSION BASED MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT; PRIORITY JOURNAL; PYROSEQUENCING; QUANTITATIVE ANALYSIS; SEMICONDUCTOR BASED NEXT GENERATION SEQUENCING; SENSITIVITY ANALYSIS; SEROUS CARCINOMA; SOLID TUMOR; SOMATIC MUTATION; THYROID CARCINOMA; TUMOR VOLUME; AMPLISEQ CANCER PANEL; COMPARATIVE STUDY; GENETICS; HIGH THROUGHPUT SEQUENCING; ION TORRENT; MASS SPECTROMETRY; MASSARRAY; METHODOLOGY; MUTANT ALLELE BURDEN; MUTANT ALLELE FREQUENCY; MUTATION; NEOPLASM; NEXT-GENERATION SEQUENCING; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SEMICONDUCTOR; SEQUENOM; TUMOR GENE;

AMPLISEQ CANCER PANEL; ION TORRENT; MASSARRAY; MUTANT ALLELE BURDEN; MUTANT ALLELE FREQUENCY; NEXT-GENERATION SEQUENCING; SEQUENOM;

DNA MUTATIONAL ANALYSIS; GENES, NEOPLASM; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASMS; POLYMERASE CHAIN REACTION; SEMICONDUCTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84899492822     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP1JUGQMW7ZNTL     Document Type: Article

References (34)

1. Beadling C, Heinrich MC, Warrick A, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn. 2011;13:504-513.
2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139. (Pubitemid 38637993)
4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
5. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311. (Pubitemid 39209661)
6. Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn. 2008;10:493-495.
7. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554. (Pubitemid 38541907)
8. Tsao H, Goel V, Wu H, et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004;122:337-341. (Pubitemid 38281053)
9. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349. (Pubitemid 46621810)
10. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
11. Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol. 2008;3:1224-1235.
12. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005;65:7276-7282. (Pubitemid 41161259)
13. Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol. 2006;126:608-615. (Pubitemid 44498512)
14. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 2005;7:413-421. (Pubitemid 41149657)
15. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005;7:396-403. (Pubitemid 41149655)
16. Smith GD, Chadwick BE, Willmore-Payne C, et al. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol. 2008;61:487-493. (Pubitemid 351518232)
17. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786-792. (Pubitemid 40271173)
18. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005;102:7665-7670.
19. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401. (Pubitemid 38938156)
20. Anderson SM. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn. 2011;11:635-642.
21. Angulo B, Garcia-Garcia E, Martinez R, et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn. 2010;12:292-299.
22. Oliner K, Juan T, Suggs S, et al. A comparability study of 5 commercial KRAS tests. Diagn Pathol. 2010;5:23.
23. Simeonov A, Nikiforov TT. Single nucleotide polymorphism genotyping using short, fluorescently labeled locked nucleic acid (LNA) probes and fluorescence polarization detection. Nucleic Adds Res. 2002;30:91.
24. Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn. 2009;11:543-552.
25. Van den Boom D, Wjst M, Everts RE. MALDI-TOF mass spectrometry. Methods Mol Biol. 2013;1015:71-85.
26. Wang Z, Portier BP, Gruver AM, et al. Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma. J Mol Diagn. 2013;15:210-219.
27. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14:178-192.
28. Routbort M, Handal B, Patel KP, et al. OncoSeek - a versatile annotation and reporting system for next generation sequencing-based clinical mutation analysis of cancer specimens. J Mol Diagn. 2012;14:747.
29. Verma S, Greaves WO, Ravandi F, et al. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol. 2012;138:153-156.
30. Beadling C, Neff TL, Heinrich MC, et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn. 2013;15:171-176.
31. Ng CK, Pemberton HN, Reis-Filho JS. Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther. 2012;12:1021-1032.
32. V600E mutations in primary and metastatic melanoma. PLoS One. 2012;7:e29336.
33. Staaf J, Isaksson S, Karlsson A, et al. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int J Cancer. 2013;132:2020-2031.
34. Staaf J, Jonsson G, Ringner M, et al. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 2011;13:R129.